Data on ORY-1001 to Be Presented at the AACR Annual Meeting 2016 in New Orleans
BARCELONA, SPAIN and CAMBRIDGE MA.
Oryzon Genomics (ISIN Code: ES0167733015), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in oncology and neurodegenerative diseases, today announced that data on ORY-1001 will be presented at the American Association for Cancer Research (AACR) Annual meeting to be held at the Ernest N. Morial Convention Center in New Orleans, Louisiana in April 16-20, 2016.